1-6 of 6
Priscilla Do
Close
Sort by
Journal Articles

Obesity Attenuates T-Cell Function Which Impacts the Efficacy of T-Cell Based Immunotherapies in Acute Lymphoblastic Leukemia

Anthony Ross, MD, Miyoung Lee, PhD, Jamie Hamilton, Raira Ank, Priscilla Do, PhD, Jamie Story, Sunil S. Raikar, MD, Erik Dreaden, PhD, Christopher C. Porter, MD, Curtis J. Henry, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-136573
Published: 2020
Journal Articles

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eileen Hu, BS, Priscilla Do, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Haiyong Peng, PhD, Lorenz Waldmeier, PhD, Roger Beerli, PhD, Christoph Rader, PhD, Ulf Grawunder, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM,PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3017.
https://doi.org/10.1182/blood.V130.Suppl_1.3017.3017
Published: 2017
Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3221.
https://doi.org/10.1182/blood.V128.22.3221.3221
Published: 2016
Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3238.
https://doi.org/10.1182/blood.V128.22.3238.3238
Published: 2016
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2016) 128 (22): 2767.
https://doi.org/10.1182/blood.V128.22.2767.2767
Published: 2016
Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Clinical Trials & Observations
Joseph A. Fraietta, Kyle A. Beckwith, Prachi R. Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, Jan Joseph Melenhorst, Shannon E. McGettigan, Danielle R. Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus
Journal: Blood
Blood (2016) 127 (9): 1117–1127.
https://doi.org/10.1182/blood-2015-11-679134
Published: 2016
Includes: Supplemental data